MDX 1342

Drug Profile

MDX 1342

Alternative Names: MDX-1342

Latest Information Update: 25 Jun 2013

Price : $50

At a glance

  • Originator Medarex
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action CD19 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Chronic lymphocytic leukaemia; Rheumatoid arthritis

Most Recent Events

  • 25 Jun 2013 No development reported - Phase-I for Chronic lymphocytic leukaemia in USA (IV)
  • 25 Jun 2013 No development reported - Phase-I for Rheumatoid arthritis in Germany (IV)
  • 25 Jun 2013 No development reported - Phase-I for Rheumatoid arthritis in Hungary (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top